DBV Raises VC To Help Treat Peanut Allergies
DBV Technologies, a French developer of non-invasive epicutaneous diagnostics and immunotherapies for peanut allergies, has raised a €6 million in second-round funding. ALK-Abello was joined by return backer Sofinnova Partners.
23 January 2009•3 mins read
